You are here

biotech

Here Are the Top Five Biotech Trends for 2023

NASDAQ

Mon, 12/19/22 - 11:23 am

personalized medicine

tissue engineering

Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’

BioPharma Dive

Wed, 12/7/22 - 09:47 am

SAGE Therapeutics

Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

BioSpace

Mon, 11/14/22 - 10:59 am

corporate culture

Moderna Therapeutics

Biotechnology Industry Gets A Boost From Community College Degrees

Forbes

Fri, 11/11/22 - 10:42 am

community colleges

drug manufacturing

J.P. Morgan Launches Life Sciences Fund to Support Early-Stage Biotech

BioSpace

Wed, 11/2/22 - 10:45 pm

Biotech Sector Thrives, Generating Nearly $3 Trillion Economic Impact - New Report Shows

BioSpace

Mon, 10/31/22 - 10:33 am

Biotech employees’ desire for freedom and flexibility is ‘here to stay,’ survey finds

Medical Marketing and Media

Thu, 10/20/22 - 11:31 pm

Despite progress, women are 'severely underrepresented' in biotech — report

Endpoints

Tue, 09/20/22 - 08:34 pm

gender discrimination

Are biotech SPACs back? Cancer-focused Apollomics next to take blank-check route

Fierce Biotech

Thu, 09/15/22 - 11:27 pm

Can biotech IPOs bounce back? Third Harmonic to test investor appetite with planned offering

BioPharma Dive

Wed, 09/14/22 - 10:11 am

Third Harmonic Bio

U.S. to spend more than $2 billion to launch Biden’s biomanufacturing initiative

Stat

Wed, 09/14/22 - 09:39 am

drug manufacturing

Biden to launch new support for U.S. biotech production

CNBC

Tue, 09/13/22 - 11:00 am

Biopharma Needs to Protect more than Crown Jewel IP to Stay Competitive

BioSpace

Fri, 09/2/22 - 12:56 pm

intellectual property

Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech

BioPharma Dive

Tue, 08/30/22 - 11:57 am

BioForest region is breaking out with innovation, talent and investment

BioSpace

Mon, 08/29/22 - 10:54 am

Washington state

After a record run, fewer biotechs are going public. Here’s how they’re performing.

BioPharma Dive

Mon, 08/29/22 - 10:31 am

Foghorn sounds another warning about the class of ‘20

EP Vantage

Thu, 08/25/22 - 10:52 am

Foghorn Therapeutics

Biotech Looks to Bounce Back in Second Half of 2022

BioSpace

Mon, 08/22/22 - 09:43 am

Q2 ‘22 was weakest quarter for biotech IPOs in more than 5 years

Fierce Biotech

Thu, 08/11/22 - 12:39 pm

Strand CEO on founder-led biotech, venture capital and the market’s retreat

BioPharma Dive

Wed, 08/3/22 - 10:56 am

Strand Therapeutics

venture capital

Pages